The human growth hormone (HGH) or somatotropin is a peptide hormone secreted by the pituitary gland that regulates cell growth, cell regeneration, cell reproduction, and metabolism contributing to the overall development of human body. The HGH levels in the human body should be optimum for normal growth and can be regulated by factors including exercise, sleep, stress, and lower glucose levels. It also help in controlling body composition, body fluids, muscle & bone growth, sugar & fat metabolism, and recovery from injury. Moreover, lower or higher levels of HGH may affect the quality of life in such way that increasing the risks of diseases (high cholesterol levels, HGH deficiency, and poor bone density). The deficiency falls under the list of endocrine condition and condition usually vary from person to person across the globe. These hormone levels decrease with age and this natural slowdown in the production of human growth hormone in human body has triggered the interest in using synthetic HGH therapies across the world. The increase in applications of human growth hormone and the awareness about the effects of these hormone in the treatment of short stature are major factors propelling the growth of this market. The Human Growth Hormone Market was expected at USD 5.0 million in 2020 and is expected to reach 10.7 USD million by 2030 growing with a CAGR of 8.0% during the forecast period.
Market Segmentation:
Based on applications, the global human growth hormone market is divided into growth hormone deficiency, Prader-Willi syndrome, Turner syndrome, small for gestational age, and others. Based on the route of administration, the market is classified into intravenous, intramuscular, subcutaneous, and oral. On basis of the distribution channel, the market is categorised as hospital pharmacy, retail pharmacy, clinic, and online pharmacy. By the region, the human growth hormone market is segmented into North America (NA), Europe (EU), Asia Pacific (APAC), and RoW.
Market Dynamics and Factors:
The rise in awareness of effectiveness & demand for cost efficient HGH therapies, increase in prevalence of serious chronic diseases (chronic kidney disease, and growth retardation), and surge in compliance for human growth hormone formulations is one of the major drivers for the growth of the global human growth hormone market. Moreover, increasing demand for human growth hormone drugs, increasing incidences of HGH deficiency diseases, growing geriatric population, and technological advancements (recombinant DNA technology) are some of the other main factors which will drive the market during forecast time. However, the stringent government approvals are responsible to restrain the market growth. Furthermore, several major players are investing heavily and collaborating among each other for the research and development of HGH drugs are also boosting the growth of these markets during the next coming years. On the rather hand, the rise in disposable income and surge in healthcare expenditure in developing economies are creating immense opportunities for the market growth during forecast timeframe. Furthermore, an illegal use of these hormone drugs in sports is adversely impacting the market growth are considered to be the challenge for human growth hormone market in upcoming years.
Geographic Analysis:
North America dominate the largest share accounted as 49.18% for the growth of the global human growth hormone market in 2017 and is anticipated to continue this trend during the forecast period. This is due to increased consumption of HGH therapies to treat various disorders (Turner syndrome), ease of availability of artificial growth hormones, and rise in R&D toward recombinant HGH in this region. In the United States, approximately 4,000 to 10,000 children and approximately 50,000 adults suffer by HGH deficiency. The largest share of the U.S. can be attributed to high healthcare expenditure, high prevalence of target diseases, and availability of reimbursements. Europe holds the second largest regional market attributed to the presence of significant market players, and favourable government initiatives towards superior healthcare facilities for the consumers. Additionally, Asia pacific is expected to fastest rate market owing to the rise in incidence of HGH deficiency disorders, penetration of leading players, and surge in disposable income during the forecast time frame. The Rapid growth in population aging, improving and modernizing healthcare infrastructure, and development of affordable orthodontics products are key factors for boosting demand for the human growth hormone market in developing country such as China, India, Brazil, and Mexico.
Competitive Scenario:
The key players of global human growth hormone markets are Genentech Inc., Lifetech Labs, GeneScience Pharmaceuticals Co. Ltd., Eli Lilly and Company, Pfizer Inc., Ipsen S.A., Biopartners GmbH, Anhui Anke Biotechnology (Group) Co. Ltd., Novartis AG, and Merck KGaA.
Human Growth Hormone (HGH) Market Report Scope
| Report Attribute | Details |
| Analysis Period | 2020–2030 |
| Base Year | 2021 |
| Forecast Period | 2022–2030 |
| Market Size Estimation | Million (USD) |
| Growth Rate (CAGR%) | 8 % |
|
| By Application (Growth Hormone Deficiency, Prader-Willi Syndrome, Turner Syndrome, Small for Gestational Age, and Others), By Route of Administration (Intravenous, Intramuscular, Subcutaneous, and Oral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, and Online Pharmacy) |
| Geographical Segmentation | North America (U.S., Canada, Mexico) Europe (UK, Germany, Italy, France, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, Rest of APAC), South America (Brazil, Argentina, Rest of SA), MEA (UAE, Saudi Arabia, South Africa) |
| Key Companies Profiled | Genentech Inc., Lifetech Labs, GeneScience Pharmaceuticals Co. Ltd., Eli Lilly and Company, Pfizer Inc., Ipsen S.A., Biopartners GmbH, Anhui Anke Biotechnology (Group) Co. Ltd., Novartis AG, and Merck KGaA. |
|
|
|
